Search hospitals > Illinois > Eureka
Illinois CancerCare-Eureka
Claim this profileEureka, Illinois 61530
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Adenocarcinoma
378 reported clinical trials
2 medical researchers
Summary
Illinois CancerCare-Eureka is a medical facility located in Eureka, Illinois. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Illinois CancerCare-Eureka is involved with conducting 378 clinical trials across 486 conditions. There are 2 research doctors associated with this hospital, such as Bryan A. Faller and James L. Wade.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
ER positive
HER2 negative
Top PIs
Bryan A. FallerCrossroads Cancer Center1 year of reported clinical research
Expert in Cancer
Expert in Breast Cancer
220 reported clinical trials
287 drugs studied
James L. WadeDecatur Memorial Hospital3 years of reported clinical research
Studies Recurrence
Studies Breast Cancer
11 reported clinical trials
20 drugs studied
Clinical Trials running at Illinois CancerCare-Eureka
Breast Cancer
Prostate Cancer
Cancer
Lung Cancer
Gastric Cancer
Non-Small Cell Lung Cancer
Bladder Cancer
Gastroesophageal Junction Adenocarcinoma
Esophageal Cancer
Esophageal Adenocarcinoma
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This study is evaluating whether a drug used to treat high blood pressure and heart failure may help prevent heart damage in patients with breast cancer.
Recruiting2 awards Phase 323 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Illinois CancerCare-Eureka?
Illinois CancerCare-Eureka is a medical facility located in Eureka, Illinois. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Illinois CancerCare-Eureka is involved with conducting 378 clinical trials across 486 conditions. There are 2 research doctors associated with this hospital, such as Bryan A. Faller and James L. Wade.
Where is Illinois CancerCare-Eureka located?
**Illinois CancerCare-Eureka Hospital**
- **Address:** 101 South Major Street, Eureka, IL 61530
- **Open:** Wednesdays, with attending physician Pankaj Kumar, M.D.
- **Website:** [www.illinoiscancercare.com](http://www.illinoiscancercare.com)
Who should I call to ask about financial aid or insurance network?
Illinois CancerCare-Eureka does not list direct contact information for financial assistance and insurance departments on their website. For general insurance inquiries, contact the Illinois Department of Insurance at DOI.InfoDesk@illinois.gov or call 866-445-5364. Financial assistance for genetic screening, targeted therapies, and tumor sequencing is available through the Illinois CancerCare Foundation and local organizations like the American Cancer Society and the Cancer Financial Assistance Coalition.
What insurance does Illinois CancerCare-Eureka accept?
Illinois CancerCare-Eureka accepts Medicare and a wide range of private insurance plans. These include Aetna HMO, PPO, POS; BCBS of Illinois PPO, POS, EPO; Beech Street PPO; Cigna/Great West Healthcare; Humana HMO, PPO; and United Health Care among others. Patients should verify physician participation in their plan and discuss pre-certification requirements with the office.
What awards or recognition has Illinois CancerCare-Eureka received?
Illinois CancerCare-Eureka, located in Eureka, Illinois, is renowned for its dedication to cancer research and quality care. It was recognized by the Alliance for Clinical Trials in Oncology as a top enroller in clinical research in 2015 and has achieved certification from the Quality Oncology Practice Initiative (QOPI®) for meeting the highest national standards in cancer care. The hospital maintains over 100 open clinical cancer research trials, underscoring its commitment to advancing cancer treatment.